GlassScriptPhysician profile
Margaret Young
NPI 1922574599
$11,225.32
in general payments reported to CMS, 2019-2025
24 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,182 · 2022: $1,164 · 2023: $3,181 · 2024: $4,277 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,551 · Food and Beverage: $4,296 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,551.28 |
| Food and Beverage | $4,295.52 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,898.31 | 2022-2025 | Corevalve Evolut R, Symplicity G3 |
| Abbott Laboratories | $3,067.84 | 2023-2025 | Mitraclip, Triclip |
| Novartis Pharmaceuticals Corporation | $1,052.37 | 2021-2024 | |
| Amgen INC. | $608.16 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.76 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $357.32 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $336.96 | 2021-2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $192.50 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $183.58 | 2021-2025 | Lifevest |
| Amarin Pharma, INC. | $157.12 | 2021-2022 | |
| Edwards Lifesciences Corporation | $120.67 | 2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $116.00 | 2023-2025 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $103.05 | 2021 | |
| Merck Sharp & Dohme LLC | $98.47 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $71.63 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $59.07 | 2023-2025 | Neoview |
| Abiomed | $45.52 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $40.87 | 2024-2025 | Evkeeza |
| Astrazeneca Pharmaceuticals LP | $40.28 | 2023-2024 | Wainua, Farxiga |
| Alnylam Pharmaceuticals INC. | $39.71 | 2025 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $36.71 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $33.99 | 2021-2025 | Nexletol |
| Pfizer INC. | $25.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.